Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.4103/0971-5851.51429
Triple negative breast cancer with isolated leptomeningeal metastasis
![](https://www.thieme-connect.de/media/10.1055-s-00050348/200802/lookinside/thumbnails/10_4103_0971-5851_51429_30-1.jpg)
Abstract
Isolated Leptomeningeal metastasis in breast cancer is rare. The diagnosis requires T1W MR scan of brain with gadolinium enhancement and demonstration of malignant cells in CSF. The treatment is palliative, which includes whole brain radiotherapy and chemotherapy.
Publication History
Article published online:
02 March 2022
© 2008. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Kaal EC, Vecht CJ. CNS complications of breast cancer: current and emerging treatment options. CNS Drugs. 2007;21(7):559-79.
- 2 Boogerd W, van den Bent MJ, Koehler PJ, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer. 2004;40(18):2726-33.
- 3 Rudnicka H, Niwiρska A, Murawska M. Breast cancer leptomeningeal metastasis-the role of multimodality treatment. J Neurooncol. 2007;84(1):57-62.
- 4 Tham YL, Hinckley L, Teh BS, Elledge R. Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report. Clin Breast Cancer. 2006;7(2):164-6.
- 5 Carmona-Bayonas A. Concurrent radiotherapy and capecitabine, followed by high-dose methotrexate consolidation, provided effective palliation in a patient with Leptomeningeal metastases from breast cancer. Ann Oncol. 2007;18(1):199-200.
- 6 Stemmler HJ, Schmitt M, Harbeck N, et al. Application of intrathecal trastuzumab (Hercept-intrade mark) for treatment ofmeningeal carcinomatosis in HER2- overexpressing metastatic breast cancer. Oncol Rep. 2006;15(5):1373-7.